NeuBase Therapeutics, Inc. - FORM 10-K - EX-23 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - December 15, 2017

Attached files

file filename
EX-32.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc.ex32-2.htm
EX-32.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex32-1.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER - NeuBase Therapeutics, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER - NeuBase Therapeutics, Inc.ex31-1.htm
EX-21 - SUBSIDIARIES OF THE REGISTRANT - NeuBase Therapeutics, Inc.ex21.htm
EX-10.11(C) - FORM OF RESTRICTED STOCK AGREEMENT - NeuBase Therapeutics, Inc.ex10-11c.htm
EX-10.11(B) - FORM OF STOCK OPTION AGREEMENT - NeuBase Therapeutics, Inc.ex10-11b.htm
10-K - ANNUAL REPORT - NeuBase Therapeutics, Inc.ohrp-10k_093017.htm
 

Ohr Pharmaceutical, Inc. 10-K

 

Exhibit 23

Consent of Independent Registered Public Accounting Firm

 

We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-201368 and 333-220487) and Form S-8 (No. 333-215382) of Ohr Pharmaceutical, Inc. of our report dated December 15, 2017, relating to the consolidated financial statements for the year ended September 30, 2017, which report appears in this Annual Report on Form 10-K for the fiscal year ended September 30, 2017.

 

/s/ MaloneBailey, LLP  
www.malone-bailey.com  
Houston, Texas  
December 15, 2017  

 

 

NeuBase Therapeutics, Inc. Reports